Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, November 08, 2016
Spanish contract development and manufacturing organization (CDMO) Idifarma has grown by more than 50%in the last two years as it continues to expand its international customer base and strengthen its specialist production capabilities.
read more
IDLogiq® innovations have been selected by the FDA for the Pilot Project Program under the DSCSA to prototype and develop a system that can address the national security of the drug supply chain.
read more
Wednesday, August 26, 2015
IDT Biologika announces today the acquisition of Gallant Custom Laboratories, based in Ontario, Canada. The transaction is to close August 31, 2015.
read more
IDT Biologika announced the NIAID has awarded the company a 10-year Indefinite Quantity, Indefinite Delivery to provide process development, manufacturing and characterization of vaccine and biologic products for infectious diseases.
read more
Friday, November 08, 2019
IDT Biologika announced the NIAID of the NIH has awarded the company a new Task Order within the 10-year IDIQ to provide process development activities and production of a vaccine against the RSV.
read more
IDT Biologika announced the NIAID of the NIH has awarded the company a new Task Order within the 10-year contract to provide manufacturing of five E. coli Master Cell Banks.
read more
IDT Biologika and Exothera announced a collaboration to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing on Modified Vaccinia Ankara (MVA) virus as a first example for IDT’s broad range ...
read more
A major manufacturer of human vaccines designed to address some of the world’s most dangerous infectious diseases, IDT Biologika today announced it has completed and certified the construction of a large-scale production facility dedicated to filling...
read more
Wednesday, September 23, 2015
IDT Biologika has announced the dedication of its first U.S. vaccine manufacturing facility in Rockville, Maryland.
read more
Completing a major expansion of its biologics and vaccines production facility in Germany late last year, IDT Biologika established highly automated filling and freeze-drying operations, establishing the basis for large scale commercial manufacturing...
read more
IGI Laboratories, a New Jersey-based specialty generic pharmaceutical company, announced that it will adopt Teligent, Inc. as its new name and will begin trading under a new symbol – TLGT – after ringing the NASDAQ Opening Bell on October 26, 2015.
read more
IGI Laboratories, Inc., a New Jersey based formulation and manufacturing company, today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to six.
read more
Tuesday, November 06, 2012
IGI Laboratories, Inc., a New Jersey based topical generic pharmaceutical company, announced today that the Company will launch its first IGI labeled generic products later this year.
read more
Thursday, December 27, 2012
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it closed a private placement on December 21, 2012 for a gross proceeds of $2.0 million. The Company issued 1,965,740 shares of the Company’s common ...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its second abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings...
read more